Physician profile
Sharon E Perry
NPI 1578972006
$6,190.93
in general payments reported to CMS, 2019-2025
12 companies · $1,268 in 2025
The $1,268 reported for 2025 was more than what 97% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $411 · 2022: $408 · 2023: $3,100 · 2024: $1,003 · 2025: $1,268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,365 · Consulting Fee: $1,325 · Travel and Lodging: $682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,364.77 |
| Consulting Fee | $1,325.00 |
| Travel and Lodging | $681.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,647.95 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $2,081.68 | 2023-2024 | Linzess |
| Qol Medical, LLC | $612.02 | 2021-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $403.20 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $233.11 | 2024-2025 | Dupixent |
| Janssen Biotech, INC. | $63.17 | 2025 | Tremfya |
| Mirum Pharmaceuticals, INC. | $35.75 | 2022-2023 | Livmarli |
| Alcresta Therapeutics, INC. | $33.08 | 2025 | Relizorb |
| Takeda Pharmaceuticals U.S.A., INC. | $26.08 | 2025 | Eohilia |
| Celgene Corporation | $18.95 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.36 | 2024 | Cyltezo |
| Celltrion USA INC. | $17.58 | 2025 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.